| Issue |
BIO Web Conf.
Volume 142, 2024
2024 International Symposium on Agricultural Engineering and Biology (ISAEB 2024)
|
|
|---|---|---|
| Article Number | 03006 | |
| Number of page(s) | 6 | |
| Section | Microbial Engineering and Biomedical Exploration | |
| DOI | https://doi.org/10.1051/bioconf/202414203006 | |
| Published online | 21 November 2024 | |
Efficacy and Safety of Different Doses of Urico-Lowering Agents in The Treatment of Gout with Hyperuricemia: A Systematic Review and Network Meta-Analysis
1 Heilongjiang Province, School of Public Health, Jiamusi University, Jiamusi 174007, China
2 Heilongjiang Province, Heilongjiang Provincial Key Laboratory of Gout Research, Jiamusi 174007, China
* Corresponding author's Email: 910236195@qq.com
Objectives: To systematically evaluate the efficacy and safety of different doses of uric acid- lowering drugs (allopurinol, febuxostat, and benzbromarone) in patients with gout with hyperuricemia by using the method of reticulated Meta-analysis. Methods: Published clinical randomized controlled trials (RCTs) on the efficacy and safety of febuxostat, allopurinol, and benzbromarone in the treatment of gout with hyperuricemia were searched. Results: A total of 17 papers randomized controlled publications met the criteria were included, including 3461 patients (The actual number of people completed 2797) patients actually completed. Mesh meta-analysis showed that 120 mg of febuxostat had better clinical efficacy than other drugs (cumulative probability ranking curve (SUCRA) was 98.5%); 120 mg of febuxostat showed better efficacy in terms of safety than other drugs (cumulative probability ranking curve (SUCRA) was 72.0%). Conclusion: The efficacy and safety of 120 mg febuxostat in the treatment of gout with hyperuricemia were superior to other uric acid lowering drugs. This review recommended 120 mg of febuxostat for the treatment of patients with gout with hyperuricemia.
© The Authors, published by EDP Sciences, 2024
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.